Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Depreciation and Depletion (2019 - 2023)

Marker Therapeutics (MRKR) has disclosed Depreciation and Depletion for 5 consecutive years, with $800000.0 as the latest value for Q1 2023.

  • On a quarterly basis, Depreciation and Depletion rose 33.33% to $800000.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $800000.0, a 63.64% decrease, with the full-year FY2022 number at $600000.0, down 71.43% from a year prior.
  • Depreciation and Depletion was $800000.0 for Q1 2023 at Marker Therapeutics, up from -$1.4 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $800000.0 in Q3 2022 to a low of -$1.4 million in Q4 2022.
  • A 5-year average of $241176.5 and a median of $270000.0 in 2020 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: soared 1566.67% in 2021, then plummeted 380.0% in 2022.
  • Marker Therapeutics' Depreciation and Depletion stood at $30000.0 in 2019, then surged by 800.0% to $270000.0 in 2020, then soared by 85.19% to $500000.0 in 2021, then tumbled by 380.0% to -$1.4 million in 2022, then surged by 157.14% to $800000.0 in 2023.
  • Per Business Quant, the three most recent readings for MRKR's Depreciation and Depletion are $800000.0 (Q1 2023), -$1.4 million (Q4 2022), and $800000.0 (Q3 2022).